Md. Rokibul Hasan Bhuiyan, Abdullah Al Mamun, Bishal Sharker, Md. Sadikuj Jaman. Anticancer activity and therapeutic uses of catechins on breast, prostate and lung cancer: Future perspective and clinical proofs. Jour of Clin Cas Rep, Med Imag and Heal Sci. 2023;3:3 https://doi.org/10.55920/JCRMHS.2023.03.001118

Jaman S, Md. Islam N, Maniruzzaman, Hossain F, Bhuiyan RH and Emaul N. Preventive and therapeutic effect of ellagic acid, sulforphane and ursolic acid on colon cancer: from cellular response to molecular mechanism of action with future perspectives. International Journal of Clinical and Medical Case Reports.2023;1–13

Sadikuj Jaman Md, Mamun AA, Bishal Sharker M, Rakib MM, Rased Rana M, Nahid Hasan M, Bhuiyan RH (2023) Curcumin, diallyl sulphide, quercetin and gallic acid uses as anticancer and therapeutic agents for breast cancer: current strategies and future perspectives. European J Med Health Sci 5:32–48

Google Scholar 

Mann J (2002) Natural products in cancer chemotherapy: past, present and future. Nat Rev Cancer 2(2):143–148. https://doi.org/10.1038/nrc723

Article  CAS  PubMed  Google Scholar 

Jaman S, Rezwan S, Alam S, Islam R, Husna AU, Sayeed S (2017) Association of mean platelet volume and platelet distribution width with HbA1c. J Endocrinol Diabetes 4:1–6. https://doi.org/10.15226/2374-6890/4/4/00183

Article  Google Scholar 

Harvey AL, Edrada-Ebel R, Quinn RJ (2015) The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov 14(2):111–129. https://doi.org/10.1038/nrd4510

Article  CAS  PubMed  Google Scholar 

Li JW, Vederas JC (2009) Drug discovery and natural products: end of an era or an endless frontier? Science 325(5937):161–165. https://doi.org/10.1126/science.1168243

Article  CAS  PubMed  Google Scholar 

Sadikuj Jaman Md, Abu Sayeed Md (2018) Ellagic acid, sulphoraphan, and ursolic acid in the prevention and therapy of breast cancer: current evidence and future perspectives. Breast Cancer 25:517

Article  PubMed  Google Scholar 

Chen M-J, Cheng Y-M, Chen C-C, Chen Y-C, Shen C-J (2017) MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM. Biochem Biophys Res Commun 483(2):840–846. https://doi.org/10.1016/j.bbrc.2017.01.012

Article  CAS  PubMed  Google Scholar 

Sengupta D, Deb M, Rath SK, Kar S, Parbin S, Pradhan N, Patra SK (2016) DNA methylation and not H3K4 trimethylation dictates the expression status of miR-152 gene which inhibits migration of breast cancer cells via DNMT1/CDH1 loop. Experiment Cell Res. 346(2):176–187. https://doi.org/10.1016/j.yexcr.2016.07.023

Article  CAS  Google Scholar 

Jiang CF, Xie YX, Qian YC et al (2021) TBX15/miR-152/KIF2C pathway regulates breast cancer doxorubicin resistance via promoting PKM2 ubiquitination. Cancer Cell Int 21:542. https://doi.org/10.1186/s12935-021-02235-w

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anaya-Ruiz M, Cebada J, Delgado-Lopez G, Sanchez-Vazquez ML, Perez-Santos M (2013) MiR-153 silencing induces apoptosis in the MDA-MB-231 breast cancer cell line. Asian Pacific J Cancer Prevent. https://doi.org/10.7314/apjcp.2013.14.5.2983

Article  Google Scholar 

Liang H, Xiao J, Zhou Z et al (2018) Hypoxia induces miR-153 through the IRE1α-XBP1 pathway to fine tune the HIF1α/VEGFA axis in breast cancer angiogenesis. Oncogene 37:1961–1975. https://doi.org/10.1038/s41388-017-0089-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng C-W, Liao W-L, Chen P-M, Jyh-Cherng Yu, Shiau H-P, Hsieh Y-H, Lee H-J, Cheng Y-C, Pei-Ei Wu, Shen C-Y (2021) MiR-139 modulates cancer stem cell function of human breast cancer through targeting CXCR4. Cancers 13(11):2582. https://doi.org/10.3390/cancers13112582

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoppe R, Achinger-Kawecka J, Winter S, Fritz P, Lo W-Y, Schroth W, Brauch H (2013) Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment. Eur J Cancer 49(17):3598–3608. https://doi.org/10.1016/j.ejca.2013.07.145

Article  CAS  PubMed  Google Scholar 

Purohit PK, Edwards R, Tokatlidis K, Saini N (2019) MiR-195 regulates mitochondrial function by targeting mitofusin-2 in breast cancer cells. RNA Biol 16(7):918–929. https://doi.org/10.1080/15476286.2019.1600999

Article  PubMed  PubMed Central  Google Scholar 

Igglezou M, Vareli K, Georgiou GK, Sainis I, Briasoulis E (2014) Kinetics of circulating levels of miR-195, miR-155 and miR-21 in patients with breast cancer undergoing mastectomy. Anticancer Res 34(12):7443–7447

PubMed  Google Scholar 

Yin R, Guo Le, Jingya Gu, Li C, Zhang W (2018) Over expressing miR-19b-1 suppress breast cancer growth by inhibiting tumor microenvironment induced angiogenesis. Int J Biochem Cell Biol 97:43–51. https://doi.org/10.1016/j.biocel.2018.02.005

Article  CAS  PubMed  Google Scholar 

Fang C, Wang F-B, Li Y, Zeng X-T (2016) Down-regulation of miR-199b-5p is correlated with poor prognosis for breast cancer patients. Biomed Pharmacother 84:1189–1193. https://doi.org/10.1016/j.biopha.2016.10.006

Article  CAS  PubMed  Google Scholar 

Cheng S, Zhang Z, Hu C, Xing N, Xia Y, Pang B (2020) Pristimerin suppressed breast cancer progression via miR-542-5p/DUB3 Axis. Onco Targets Ther 7(13):6651–6660. https://doi.org/10.2147/OTT.S257329

Article  Google Scholar 

Lyu H, Wang S, Huang J, Wang B, He Z, Liu B (2018) Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer. Cancer Lett 420:97–108. https://doi.org/10.1016/j.canlet.2018.01.065

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shen L, Li J, Xu L, Ma J, Li H, Xiao X, Zhao J, Fang L (2012) miR-497 induces apoptosis of breast cancer cells by targeting Bcl-w. Exp Ther Med 3(3):475–480. https://doi.org/10.3892/etm.2011.428

Article  CAS  PubMed  Google Scholar 

Deng X, Zhao Y, Wang B (2015) miR-519d-mediated downregulation of STAT3 suppresses breast cancer progression. Oncol Rep 34(4):2188–2194. https://doi.org/10.3892/or.2015.4160

Article  CAS  PubMed  Google Scholar 

Danza K, De Summa S, Pinto R, Pilato B, Palumbo O, Merla G, Simone G, Tommasi S (2015) MiR-578 and miR-573 as potential players in BRCA-related breast cancer angiogenesis. Oncotarget 1(6):471–483. https://doi.org/10.18632/oncotarget.2509

Article  Google Scholar 

Muluhngwi P, Klinge CM (2021) Identification and roles of miR-29b-1-3p and miR29a-3p-regulated and non-regulated lncRNAs in endocrine-sensitive and resistant breast cancer cells. Cancers 13(14):3530. https://doi.org/10.3390/cancers13143530

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu Q, Zhang X, Zai H-Y, Jiang W, Zhang K-J, Yu-Qiong He YuHu (2021) circSLC8A1 sponges miR-671 to regulate breast cancer tumorigenesis via PTEN/PI3k/Akt pathway. Genomics 113(1):398–410. https://doi.org/10.1016/j.ygeno.2020.12.006

Article  CAS  PubMed  Google Scholar 

Jaman MS, Rahaman MS, Swarma RR, Mahato J, Siddique MAE, Ayeshasiddika M (2018) Diabetes and red blood cell parameters. Ann Clin Endocrinol Metabol 2:001–009. https://doi.org/10.29328/journal.acem.1001004

Article  Google Scholar 

Li X, Zhang R, Liu Z, Li S, Xu H (2017) The genetic variants in the PTEN/PI3K/AKT pathway predict susceptibility and CE (A) F chemotherapy response to breast cancer and clinical outcomes. Oncotarget 21(8):20252–20265. https://doi.org/10.18632/oncotarget.15690

Article  Google Scholar 

Zhang X-Y, Mao L (2021) Circular RNA Circ_0000442 acts as a sponge of MiR-148b-3p to suppress breast cancer via PTEN/PI3K/Akt signaling pathway. Gene 766:145113

Article  CAS  PubMed  Google Scholar 

Wang F, Li L, Chen Z, Zhu M, Gu Y (2016) MicroRNA-214 acts as a potential oncogene in breast cancer by targeting the PTEN-PI3K/Akt signaling pathway. Int J Mol Med 37(5):1421–1428. https://doi.org/10.3892/ijmm.2016.2518

Article  CAS  PubMed  Google Scholar 

Wang L-L, Hao S, Zhang S, Guo L-J, Chun-Yan Hu, Zhang G, Gao Bo, Zhao J-J, Jiang Y, Tian W-G, Wang J, Luo D-L (2017) PTEN/PI3K/AKT protein expression is related to clinicopathological features and prognosis in breast cancer with axillary lymph node metastases. Hum Pathol 61:49–57. https://doi.org/10.1016/j.humpath.2016.07.040

Article  CAS  PubMed